Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Letters to the Editor

Reply

Kenji Toide, Hiroshi Yamazaki and Tetsuya Kamataki
Kenji Toide
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yamazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Kamataki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

We read carefully the letter from Dr. Landi et al. regarding our article published recently on polymorphic inducibility of CYP1B1 mRNA (1) . Dr. Landi et al. insisted in their letter that both the concentrations of dioxins and the expression levels of CYP1B1 mRNA in human lymphocytes were log-normally distributed in 71 subjects from Seveso, Italy, which is a major point to be discussed in this reply. Our data in Japanese (1) are different from their observations. When we reexamined our original data set previously published (1) , we found that the concentrations of dioxins were log-normally distributed (P = 0.31, Shapiro-Wilk test) as in their suggestion, whereas the expression levels of CYP1B1 mRNA (P = 0.02) in 72 Japanese subjects were not. The latter results indicated that an unknown factor(s) might be responsible for the expression levels of CYP1B1 mRNA in 72 Japanese subjects.

In our article (1) , it was suggested that the inducibility of CYP1B1 mRNA, which was defined as the ratio of the amounts of CYP1B1 mRNA to the concentrations of dioxins in plasma, trimodally distributed in a probit-linear plot on the original scale. This individual variation in the inducibility of CYP1B1 mRNA, therefore, would be the factor for the nonnormal distribution of the expression level of CYP1B1 mRNA in Japanese subjects. Dr. Landi et al. suggested in their letter that the inducibility of CYP1B1 mRNA in 72 Japanese subjects might be a simple log-normal distribution as well as in their 71 subjects from Seveso. We do not know how they drew the curve. According to our calculation, the curve was not a clear simple log-normal distribution (Fig. 1)⇓ . The curve certainly showed a trimodal distribution in a probit-log plot (this Fig. 1⇓ ), as well as in a probit-linear plot [original Fig. 2 in our article (1)] . Therefore, the 72 Japanese subjects in our study could be divided into three groups according to the inducibility of CYP1B1 mRNA according to either normal- or log-normal distributions. In agreement with the previous report by Kellermann et al. (2) , we found a similar trimodal distribution in the inducibility of CYP1B1 mRNA based on the calculated ratio of the amounts of CYP1B1 mRNA to the concentrations of dioxins in plasma. At present, we are evaluating the aryl hydrocarbon hydroxylase (AHH) activity of CYP1B1 in human lymphocytes. We are also carrying out studies for identifying the genetic factor(s) for trimodal distribution of CYP1B1 inducibility in human white cells in Japanese.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Probit plots for the distribution of CYP1B1 mRNA inducibility in human leucocytes. Log scales are shown. The ratio between the amount of CYP1B1 mRNA (molecules/107 molecules of 18S rRNA) and the concentration of dioxins (pg TEQ/g lipid) is defined as the inducibility of CYP1B1.

  • Received May 28, 2003.
  • Accepted June 18, 2003.

References

  1. ↵
    Toide K., Yamazaki H., Nagashima R., Itoh K., Iwano S., Takahashi Y., Watanabe S., Kamataki T. Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiol. Biomark. Prev., 12: 219-222, 2003.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Kellermann G., Shaw C. R., Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med., 289: 934-937, 1973.
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 12 (10)
October 2003
Volume 12, Issue 10
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reply
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
Citation Tools
Reply
Kenji Toide, Hiroshi Yamazaki and Tetsuya Kamataki
Cancer Epidemiol Biomarkers Prev October 1 2003 (12) (10) 1118;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reply
Kenji Toide, Hiroshi Yamazaki and Tetsuya Kamataki
Cancer Epidemiol Biomarkers Prev October 1 2003 (12) (10) 1118;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Shift Work, Chronotype, and Cancer Risk—Response
  • Shift Work, Chronotype, and Cancer Risk—Letter
  • Night Shift Work Increases Cancer Risk of Women—Letter
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement